Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents

HIV is an independent risk factor of cardiovascular disease (CVD); therefore, perinatally HIV-infected (PHIV) children potentially have a greater CVD risk at older age. Lipoprotein(a) (Lp(a)) is an established risk factor for CVD in the general population. To evaluate a potential increased CVD risk...

Full description

Bibliographic Details
Published in:	Viruses
Main Authors:	Jason G. van Genderen, Malon Van den Hof, Claudia G. de Boer, Hans P. G. Jansen, Sander J. H. van Deventer, Sotirios Tsimikas, Joseph L. Witztum, John J. P. Kastelein, Dasja Pajkrt
Format:	Article
Language:	English
Published:	MDPI AG 2021-10-01
Subjects:	human immunodeficiency virus cardiovascular disease apolipoproteins dyslipidemia atherosclerotic cardiovascular disease
Online Access:	https://www.mdpi.com/1999-4915/13/10/2067

Similar Items

Lipoprotein(a): Emerging insights and therapeutics
by: Gurleen Kaur, et al.
Published: (2024-06-01)

Lipoprotein(a) induces caspase-1 activation and IL-1 signaling in human macrophages
by: Martina B. Lorey, et al.
Published: (2023-05-01)

Effectiveness of Lipid-lowering Therapy for the Secondary Prevention and Achievement of Therapeutic Goals in Atherosclerotic Cardiovascular Diseases in Accordance with the American College of Cardiology/American Heart Association 2018 Guidelines on the Management of Blood Cholesterol
by: Christy Sojan, et al.
Published: (2024-04-01)

Egyptian practical guidance in lipid management 2020
by: Hesham Salah El Din Taha, et al.
Published: (2021-02-01)

Lipoprotein(a) as a risk factor for cardiovascular diseases - focus on ischemic stroke (a position paper)
by: Ia. B. Skiba, et al.
Published: (2024-06-01)

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)
by: Frederick Berro Rivera, MD, et al.
Published: (2025-02-01)

Plasma Lipidomic Profiles in cART-Treated Adolescents with Perinatally Acquired HIV Compared to Matched Controls
by: Julie van der Post, et al.
Published: (2024-04-01)

In-hospital and mid-term follow-up of low-density lipoprotein cholesterol and target-goal attainment among patients with acute cerebral infarction: a retrospective study
by: Zhong Chen, et al.
Published: (2024-02-01)

Composite dietary antioxidant index is inversely and nonlinearly associated with cardiovascular disease, atherosclerotic cardiovascular disease, and cardiovascular mortality in people with dyslipidemia: evidence from NHANES 2001–2018
by: Yan Jiang, et al.
Published: (2025-01-01)

Lipoprotein Metabolism, Dyslipidemia, and Lipid-Lowering Therapy in Women: A Comprehensive Review
by: Jakub Michal Zimodro, et al.
Published: (2024-07-01)

Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk
by: Michaela B. Rehman, et al.
Published: (2024-09-01)

Hyperlipidemia and Cardiovascular Risk in Children and Adolescents
by: Francesca Mainieri, et al.
Published: (2023-03-01)

Ersonified diagnostic and correction dyslipidemia approach by profiling of apolipoproteins
by: M. A. Kachkovsky, et al.
Published: (2020-12-01)

Emerging Triglyceride-Rich Lipoprotein Targeted Therapies: An Unmet Need in Cardiometabolic Disease
by: Jorge Ferreira, et al.
Published: (2025-08-01)

Therapeutic Management of LDL-C: Efficacy and Economic Impact Assessment
by: Abdallah Elshafeey
Published: (2025-05-01)

Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment
by: Federica Galimberti, et al.
Published: (2023-09-01)

Factors Associated With Enhanced Low‐Density Lipoprotein Cholesterol Lowering With Bempedoic Acid
by: Christie M. Ballantyne, et al.
Published: (2022-08-01)

A Comparison of Lipids and apoB in Asian Indians and Americans
by: Kavita Singh, et al.
Published: (2021-01-01)

Prevalence and Risk Factors for Atherosclerotic Cardiovascular Disease in 7704 Individuals: An Analysis from the Greek Registry for the Prevalence of Familial Hypercholesterolemia (GRegistry-FH)
by: Genovefa Kolovou, et al.
Published: (2024-12-01)

Establishment and Promotion of a Dyslipidemia Management and Control System Grounded on Hierarchical Medical Treatment
by: ZHANG Long, LI Jianping
Published: (2024-12-01)

Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk
by: Tamara Glavinovic, et al.
Published: (2022-10-01)

Gender differences in 7 years trends in cholesterol lipoproteins and lipids in India: Insights from a hospital database
by: Rajeev Gupta, et al.
Published: (2016-01-01)

Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Low‐Density Lipoprotein Cholesterol—The Framingham Heart Study
by: Mehdi Afshar, et al.
Published: (2020-09-01)

Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice
by: A. I. Sapina, et al.
Published: (2025-01-01)

Preventive cardiology as a dedicated clinical service: The past, the present, and the (Magnificent) future
by: Michael D. Shapiro, et al.
Published: (2020-03-01)

Dyslipidemia in youth: Epidemiology, pathophysiology, screening, management, and treatment: A review of the literature
by: Shahla V Esfarjani, et al.
Published: (2022-01-01)

The functions of apolipoproteins and lipoproteins in health and disease
by: Zijun Ma, et al.
Published: (2024-10-01)

Lipoprotein(a), family history, and incidence of premature ASCVD events in a pooled US cohort
by: Yihang Fan, et al.
Published: (2025-12-01)

Temporal trends in lipoprotein(a) testing among United States veterans from 2014 to 2023
by: Sofia E. Gomez, et al.
Published: (2024-12-01)

Genetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated Cardiovascular Risk
by: Annabelle Santos Volgman, et al.
Published: (2024-06-01)

Efficacy and safety of drugs in residual cardiovascular risk: A systematic review of the literature
by: Mario Andres Hernandez-Sómerson, et al.
Published: (2024-09-01)

Lipoprotein(a) as underestimated cardiovascular risk factor in Russia. Time to introduce into clinical practice
by: O. I. Afanasyeva, et al.
Published: (2024-10-01)

Smoking and apolipoprotein levels: A meta-analysis of published data
by: Alba Romero Kauss, et al.
Published: (2022-01-01)

Impaired sensitivity to thyroid hormones is associated with ASCVD risk factors in Beijing in euthyroid population: a cross-sectional study
by: Lintao Shi, et al.
Published: (2025-07-01)

Temporal trends, in-hospital outcomes, and risk factors of acute myocardial infarction among patients with epilepsy in the United States: a retrospective national database analysis from 2008 to 2017
by: Zhemin Pan, et al.
Published: (2024-08-01)

Pregnancy History at 40 Years of Age as a Marker of Cardiovascular Risk
by: Liv G. Kvalvik, et al.
Published: (2024-03-01)

Is there a benefit of aspirin therapy for primary prevention to reduce the risk of atherosclerotic cardiovascular disease in patients with elevated Lipoprotein (a)—A review of the evidence
by: Mohamad Hekmat Sukkari, et al.
Published: (2023-09-01)

Development and validation of an isoform-independent monoclonal antibody–based ELISA for measurement of lipoprotein(a)
by: Santica M. Marcovina, et al.
Published: (2022-08-01)

Lipoprotein (a) Screening, and What's Next?
by: Pasławska Anna, et al.
Published: (2024-12-01)

Lipoprotein(a) in the diagnosis of cardiovascular risk. The values of lipoprotein (a) and apolipoprotein B in the adult population of Krasnoyarsk
by: V. S. Emelyanchik, et al.
Published: (2023-08-01)